Step Therapy for IBD: What “Fail First” Means and How Appeals Work

If your gastroenterologist prescribed a biologic and the insurer came back asking you to try something cheaper first, you have run into step therapy. Plan documents also call it "fail first," and the phrase is literal: coverage for the drug your doctor chose is withheld until the record shows you tried and did not succeed on the drug the plan prefers. For inflammatory bowel disease, where a delayed start can mean months of steroids, the difference between a denial that sticks and one that gets overturned usually comes down to how well your prior treatment history is documented. This article explains what fail-first rules require, which appeal rights apply to your specific plan, and what a step therapy appeal needs to contain.

What Step Therapy and Fail First Actually Mean

Step therapy is a coverage rule, not a medical recommendation. The insurer agrees the drug is appropriate for someone with your diagnosis but requires documentation that one or more lower-cost drugs were tried first. In IBD, the required steps commonly involve corticosteroids and immunosuppressants, which the National Institute of Diabetes and Digestive and Kidney Diseases notes should only be used short term in the case of steroids. Payers frequently apply these edits in ways that clinicians dispute. In a survey of 84 gastroenterologists, more than 75 percent reported denials for infliximab and vedolizumab dose modifications and for first-time ustekinumab therapy, and 99 percent said authorization delays harmed patient care. The delays are measurable. A study of pediatric IBD patients found that prior authorizations involving appeals or step therapy added roughly 25 days before a biologic could start, with a 12.9 percent increase in hospitalization, surgery, or emergency visits within six months.

Which Rules Apply to Your Plan

The appeal path depends on who regulates your coverage, and this is the first thing to determine. If you have an individual or small group plan bought through the marketplace, federal rules require the insurer to decide a standard formulary exception request within 72 hours and an expedited request based on exigent circumstances within 24 hours, with denials reviewable by an independent review organization on the same clock, per 45 CFR 156.122. If your coverage comes from an employer, 29 CFR 2560.503-1 governs: you get at least 180 days to file an internal appeal, urgent care determinations must come within 72 hours, and pre-service claims must be decided within 15 days. Self-funded employer plans are generally outside state insurance law, so state step therapy statutes may not help you.

Medicare works differently again. Part D plan sponsors must run an exceptions process in which your prescriber submits a supporting statement, and the plan cannot treat that statement as an automatic approval, under 42 CFR 423.578. Expedited Part D determinations carry a 24-hour deadline, and a missed deadline is itself treated as an adverse decision that must be forwarded to an independent review entity. Medicare Advantage plans may apply step therapy to Part B drugs, including infusions, but only to new administrations using at least a 365-day lookback, and the program must be reviewed by a pharmacy and therapeutics committee, per 42 CFR 422.136.

The Exception Criteria That Win Overrides

State step therapy override laws, which apply to fully insured plans, converge on a similar set of grounds. Virginia's statute is representative and requires a carrier to grant an exception when the required drug is contraindicated, when it is expected to be ineffective given the patient's clinical characteristics, when the patient already tried it and discontinued it for lack of efficacy, diminished effect, or an adverse event, or when the patient is currently stable on the prescribed drug. That statute also requires a response within 72 hours of receipt including weekends, or 24 hours under exigent circumstances. Criteria and deadlines differ by state, so check your own insurance department's rules before assuming the numbers above apply to you. Where no state law applies, the same four arguments still work, because they map onto medical necessity.

Building the Prior-Therapy Record

Every one of those criteria is an evidentiary claim about your past. An appeal succeeds when the chart can prove, drug by drug, what you took, at what dose, for how long, and why it stopped. Vague entries such as "failed anti-TNF" invite denials; a dated record showing induction and maintenance dosing, a documented loss of response, and the objective marker that changed is much harder to refuse. Objective evidence matters because payers weigh it. In a study of 220 IBD patients needing biologic dose escalation, approvals took a median of 7 days but stretched to 29 days when appeals were involved, and longer delays were associated with less improvement in C-reactive protein. Guideline citations strengthen the file as well, since payer criteria often lag published recommendations from the ACG guideline on ulcerative colitis in adults and the ACG guideline on management of Crohn's disease in adults.

The Appeal Checklist

Three categories of documentation carry most step therapy appeals.

• Prior therapy timeline: drug name, start and stop dates, doses, and the specific reason for discontinuation, including adverse events and antibody results
• Objective disease evidence: C-reactive protein, fecal calprotectin, endoscopy or imaging findings, steroid exposure, and hospitalizations
• Regulatory and clinical basis: the exception criterion you are invoking, the guideline supporting the requested drug, and the plan's own coverage policy language

Request the denial code and its meaning along with the full claim file, which plans subject to 45 CFR 147.136 must supply free of charge, and note that external review requests are generally due within four months of the denial notice. Ask for a peer-to-peer review with a gastroenterologist, since 95 percent of IBD specialists surveyed said peer reviewers should be gastroenterologists rather than other specialties.

Why the Record Matters More Than the Argument

Administrative burden is a known feature of this system rather than an accident. A national survey of gastroenterology providers found that nearly 94 percent reported high or extremely high prior authorization burden, and 54.4 percent said at least one patient had a serious adverse event because of authorization delays. Practices have responded by treating prior authorization navigation as an advocacy skill. Patients can do the same by keeping their own prior-therapy timeline current between appointments, so that when a fail-first denial arrives, the evidence supporting an override already exists in dated, specific form rather than being reconstructed from memory under a 72-hour clock.